Drugs / 68Ga-FF58
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT04712721 | Oct 2021 → Jun 2024 | brain neoplasm, gastroesophageal adenocarcinoma, glioblastoma, pancreatic ductal adenocarcinoma | Novartis Pharmaceuticals | Terminated | No outcome recorded Stop: Business |
| Phase 11 trial | ||||||
| Phase 1 | NCT05977322 | Oct 2023 → Dec 2024 | gastroesophageal adenocarcinoma, glioblastoma, pancreatic ductal adenocarcinoma | Novartis Pharmaceuticals | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 68Ga-FF58 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05977322 ↗ |
| Modality | Diagnostic / imaging agent | “positron emission tomography (PET) imaging” NCT04712721 ↗ |
| Route | Intravenous | “Single intravenous radiolabeled gallium FF58 injection” NCT04712721 ↗ |